Financial

August 31, 2012

Janssen-Cilag International NV (Janssen) Submits European Marketing Authorisation Application for Investigational Multi-Drug Resistant Tuberculosis Treatment Bedaquiline

Financial

July 17, 2012

Johnson & Johnson Reports 2012 Second-Quarter Results

Sales of $16.5 Billion decreased 0.7% Versus 2011 Second Quarter; Second-Quarter EPS was $0.50Excluding Special Items, 2012 Second-Quarter EPS of $1.30 increased 1.6%*

Learn more

Financial

July 2, 2012

Janssen Research & Development Submits New Drug Application to FDA for Investigational Multi-Drug Resistant Tuberculosis Treatment Bedaquiline (TMC207)

Learn more

Financial

June 18, 2012

Johnson & Johnson to Host Analyst Conference Call on Second-Quarter Results

Learn more

Financial

May 31, 2012

ASP Features Education And Innovation In The Fight Against Infection At APIC’s 39th Annual Educational Conference

Workshop and CE Study Guide on the Role of the Environment in HAI Transmission Available at ASP Booth #500

Learn more

Financial

May 29, 2012

Electronic Reminder System Improves Contact Lens Compliance, Study Shows

ACUMINDER® Tool Improves Contact Lens Wearing Behavior

Learn more

Financial

May 25, 2012

UV-Blocking Contact Lenses May Have an Effect on Maintaining Eyes’ Macular Pigment Density, Study Suggests

Learn more

Financial

May 2, 2012

Johnson & Johnson to Participate In 2012 Deutsche Bank Securities, Inc. 37th Annual Health Care Conference

Learn more

Financial

April 10, 2012

Johnson & Johnson to Host Analyst Conference Call on First-Quarter Results

Learn more

Search Results

No Results

Financial